Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1056-1063

John Wiley & Sons Inc

Access to resources Recommend Favorite

An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1395-1405

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of hepatic impairment on lenvatinib pharmacokinetics following single‐dose oral administration

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 3, 2015-03 ,pp. : 317-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end‐stage renal disease

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 32, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study

By Keller G.A.   Czerniuk P.   Bertuola R.   de Mena F.   Simoni M.V.   Assefi A.R.   Di Girolamo G.  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2203-2211

Informa Healthcare

Access to resources Recommend Favorite